Latest reported quarter: ANNUAL, ended Dec 2025
| Line item | 2025 ANNUAL | 2024 ANNUAL | 2023 ANNUAL | 2022 ANNUAL | 2021 ANNUAL |
|---|---|---|---|---|---|
| Other Operating Expenses | $4.00M | -$49.00M | $141.00M | $153.00M | $101.00M |
| Operating Profit | -$149.00M | $58.00M | -$3.00M | -$35.00M | -$412.00M |
| Diluted EPS | -$0.60 | $0.37 | -$0.05 | -$0.17 | -$0.48 |
| -Selling & Marketing Expense | $159.00M | $178.00M | $164.00M | $164.00M | $109.00M |
| Selling and Admin Expenses | $159.00M | $178.00M | $164.00M | $164.00M | $109.00M |
| Operating Expense | $163.00M | $129.00M | $305.00M | $317.00M | $210.00M |
| Gross Profit | $14.00M | $187.00M | $302.00M | $282.00M | -$202.00M |
| Cost of Revenue | $3.71B | $3.59B | $3.29B | $3.04B | $2.26B |
| Total Operating Revenue | $3.72B | $3.78B | $3.59B | $3.33B | $2.06B |
| Total Revenue as Reported | $3.72B | $3.78B | $3.59B | $3.33B | $2.06B |
| Net Non-Operating Interest Income (Expense) | $15.00M | $28.00M | $35.00M | $0.00 | -$27.00M |
| Non-Operating Interest Income | $26.00M | $32.00M | $36.00M | $10.00M | $2.00M |
| Basic EPS | -$0.60 | $0.37 | -$0.05 | -$0.17 | -$0.48 |
| Net Income to Common Stockholders | -$137.00M | $84.00M | -$11.00M | -$37.00M | -$102.00M |
| Other Preferred Stock Dividends | $0.00 | $1.00M | $0.00 | $0.00 | $0.00 |
| Net Income to Parent Company | -$137.00M | $85.00M | -$11.00M | -$37.00M | -$102.00M |
| Profit from Continuing Operations | -$137.00M | $85.00M | -$11.00M | -$37.00M | -$102.00M |
| Net Profit | -$137.00M | $85.00M | -$11.00M | -$37.00M | -$102.00M |
| Tax | $3.00M | $1.00M | $43.00M | -$8.00M | -$42.00M |
| Pretax Profit | -$134.00M | $86.00M | $32.00M | -$45.00M | -$144.00M |
| Non-Operating Interest Expense | $11.00M | $4.00M | $1.00M | $10.00M | $29.00M |
| Other Income (Expense) | – | – | – | -$10.00M | $295.00M |
| -Less:Restructuring and Mergern & Acquisition | – | – | – | $10.00M | $0.00 |
| Special Income (Charges) | – | – | – | -$10.00M | $295.00M |
| -Less:Other Special Charges | – | – | – | – | -$295.00M |
No comments yet — be the first to weigh in on ULCC.